Alborz Hassankhani
Clinical Cardiac Electrophysiology · la Mesa, CANPI 1013022615
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 94.4% of the total across 755 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 50 manufacturers, the largest accounting for just 15.4% — the pattern of someone who eats at a lot of different presentations. That places this record below the midpoint for clinical cardiac electrophysiology clinicians in CA, where the typical reported total is $26,911.
Across 755 payments — averaging $26.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$3K
- Abbott$3K
- Medtronic$2K
- Novartis$2K
- AstraZeneca$1K
- Bayer$769
- plus $9K from 44 others
Across 6 payments — averaging $1170.08 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boston Scientific$7K
What the payments were for
- Travel & lodging$1,1276%
- Food & beverage$19,14894%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AVEIR$902
- Rapiblyk$541
- Watchman$469
- Kerendia$387
- NUCALA$367
- DUPIXENT$361
- Reveal LINQ$294
- LINQ II$289
- OPTIMIZER$263
- Barostim Neo System$255
- OFEV$250
- FARXIGA$250
- XARELTO$241
- Inpefa$238
- LifeVest$225
- QUADRA ASSURA$160
- LEQVIO$139
- MitraClip$137
- ENSITE$137
- EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX$131
How this compares
$20,275 in reported general payments places this provider in the 40th percentile of 290 clinical cardiac electrophysiology providers in California.
See all clinical cardiac electrophysiology providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 237 | $262,201 |
| EliquisApixaban | 246 | $258,739 |
| FarxigaDapagliflozin Propanediol | 91 | $94,539 |
| XareltoRivaroxaban | 51 | $58,846 |
| JardianceEmpagliflozin | 28 | $33,845 |
| VerquvoVericiguat | 21 | $16,812 |
| MultaqDronedarone Hcl | 15 | $11,710 |
| DapagliflozinDapagliflozin Propanediol | 13 | $8,888 |
| Amiodarone Hcl | 80 | $4,098 |
| Flecainide Acetate | 101 | $3,889 |
| Metoprolol Succinate | 173 | $2,424 |
| Atorvastatin Calcium | 120 | $1,463 |
| Acebutolol Hcl | 34 | $1,388 |
| Ranolazine ErRanolazine | 11 | $996 |
| Losartan Potassium | 110 | $949 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $1,786 | $262,201237 claims |
| PfizerEliquis | $753 | $258,739246 claims |
| AstraZenecaFarxiga | $1,253 | $94,53991 claims |
| Johnson & JohnsonXarelto | $566 | $58,84651 claims |
| Boehringer IngelheimJardiance | $767 | $33,84528 claims |
| MerckVerquvo | $670 | $16,81221 claims |
| Sanofi-aventis U.S. LLCMultaq | $79 | $11,71015 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 290 clinical cardiac electrophysiology providers in California.
Other clinical cardiac electrophysiology in la Mesa
- Peter Belottla Mesa$112K
- Shephal DoshiSanta Monica$2.1M
- Jonathan HsuSan Diego$1.2M
- Leslie SaxonLos Angeles$1.1M
- Rahul BhardwajLoma Linda$935K
- Nicholas Olsonla Jolla$801K
- Jonathan DukesVentura$775K
- Brett GidneySanta Barbara$756K
- John Rogersla Jolla$738K
- Rajesh BankerNewport Beach$538K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.